Two distinct coverages, frequently confused

D&O vs E&O insurance for life sciences. Different policies, different triggers.

D&O (Directors and Officers liability) and E&O (Errors and Omissions, also called professional liability) sound similar and are sometimes treated as interchangeable in casual conversation. They are not. They cover fundamentally different exposures, are written by different specialty markets, and need to be sized against different threat profiles.

For life-sciences operators, most need at least one and many need both. The decision is not "D&O or E&O" but rather "what does each cover that the other does not, and which exposures apply to me."

Last updated 2026-05-12

Side-by-side

Eight dimensions where the policies diverge.

Dimension

D&O (Directors and Officers)

E&O (Errors and Omissions / Professional Liability)

Who is covered

Directors and officers in their personal capacity, plus (Side B/C) the company indemnifying them. Covers governance acts.

The company (and individuals acting in scope of work) for errors in services delivered. Covers professional acts.

Primary trigger

Wrongful act by a director or officer in their corporate capacity — breach of fiduciary duty, misrepresentation, mismanagement, regulatory investigation.

Wrongful act in the rendering of professional services — design error, analytical error, advice that caused economic loss.

Typical claimants

Shareholders, investors, regulators (SEC, FDA), employees alleging governance failure, third parties alleging misrepresentation.

Clients/sponsors/customers alleging service errors, often without physical injury (economic loss).

Policy form

Claims-made with prior-acts and Side A/B/C coverage components.

Claims-made with retroactive date.

Common limits

$3M-$25M+ depending on stage, public/private status, board composition, and prior litigation.

$1M-$10M depending on revenue, service scope, and sponsor MSA requirements.

Sponsor MSA requirement

Rarely required by sponsor MSAs explicitly; sometimes required by investor agreements or strategic-partner diligence.

Often required by sponsor MSAs for CDMOs with development scope and for CROs as a primary coverage line.

Where it matters most

Clinical-stage biotech, public-company life sciences, venture-backed operators with active investor scrutiny.

CROs, CDMOs with development services, diagnostic labs, contract testing labs, any operator providing analytical or advisory services.

Why operators sometimes need both

Protects individual directors and officers against personal-capacity claims.

Protects the company against service-error claims that products liability and CGL would exclude.

The confusion source

Both are claims-made management-lines policies. That is where the similarity ends.

Both policies are written on claims-made forms with retroactive dates, and both are commonly grouped by brokers under "management liability" or "specialty lines." That structural similarity is the source of the confusion. But what they cover is unrelated. D&O answers "did a director or officer breach their duties in governing the company?" E&O answers "did our service delivery contain an error that caused economic harm to a customer?"

A wrongful termination claim against the CEO triggers D&O (Side B/C) and EPLI. A failed CDMO formulation batch triggers E&O. A securities-class-action against a public biotech triggers D&O. A CRO data integrity error in a regulatory submission triggers E&O. The same operator can need both, and substituting one for the other leaves real coverage gaps.

Frequently asked

Common questions from CDMO and CRO buyers

What is the difference between D&O and E&O insurance?

D&O (Directors and Officers liability) protects individual directors and officers against personal-capacity claims arising from governance acts — breach of fiduciary duty, regulatory investigations, misrepresentation. E&O (errors and omissions, also called professional liability) protects the company against claims arising from errors in services delivered. They have different triggers, different claimants, and different sizing logic.

Does a CDMO need both D&O and E&O?

Often yes. E&O is increasingly required by sponsor MSAs for CDMOs with development scope (formulation, analytical, scale-up). D&O is not typically MSA-required but is necessary if the CDMO has investor governance, board exposure, or any meaningful regulatory investigation risk. Mid-sized and larger CDMOs typically carry both.

Does a CRO need D&O if it has E&O?

They cover unrelated exposures. E&O protects against service-delivery errors (the dominant CRO exposure). D&O protects directors and officers personally. A privately-held CRO with limited investor governance may operate without D&O; a venture-backed or public CRO almost always needs both.

Why is biotech D&O so expensive relative to other industries?

Biotech D&O underwriting prices three concentrated exposures: securities-class-action risk for public biotechs (settlement frequency is high), regulatory investigation defense (FDA, SEC), and investor disputes around clinical-trial outcomes. Pre-IPO biotechs already face elevated D&O premium relative to operating companies at comparable revenue.

What is "Side A" D&O coverage?

Side A covers individual directors and officers when the company cannot indemnify them — typically because of insolvency, regulatory bar, or contractual constraint. For pre-revenue clinical-stage biotechs with constrained working capital, Side A is the most important D&O component because the company may not be able to step in to defend its directors.

Does E&O cover failed batches at a CDMO?

It depends on what caused the batch failure. If the failure was a formulation error or analytical-method error (i.e., a development-services error), E&O typically responds. If the failure was a manufacturing-execution error producing a physical product defect, products liability typically responds. Many real claims have both elements and require coordination between policies.

Biotech practice →CRO practice →D&O clause →E&O clause →

Free coverage review